|
|
| Reporter | guest | Assigned To | | |
|---|
| Priority | normal | Severity | minor | Reproducibility | have not tried |
|---|
| Status | new | Resolution | open | |
|---|
| Platform | yAijsFVDvFMm | OS | CTeQykJDbaWZdVCk | |
|---|
|
|
| Summary | 0022432: Have you got any qualifications? [url=https://www.valeriecolasdesfrancs.com/rogaine-heart-tezr]rogaine funciona mesmo[/url] Han |
|---|
| Description | Have you got any qualifications? [url=https://www.valeriecolasdesfrancs.com/rogaine-heart-tezr]rogaine funciona mesmo[/url] Hanmi's potential encroachment poses a threat to AstraZeneca, which is facing the near-term expiration of U.S. patents covering its two top-selling drugs - Nexium, which loses U.S. protection in 2014, and the cholesterol pill Crestor, which will go off-patent in 2016. As a result, sales at the company are set to fall by several billion dollars.
|
|---|
| Steps To Reproduce | Have you got any qualifications? [url=https://www.valeriecolasdesfrancs.com/rogaine-heart-tezr]rogaine funciona mesmo[/url] Hanmi's potential encroachment poses a threat to AstraZeneca, which is facing the near-term expiration of U.S. patents covering its two top-selling drugs - Nexium, which loses U.S. protection in 2014, and the cholesterol pill Crestor, which will go off-patent in 2016. As a result, sales at the company are set to fall by several billion dollars.
|
|---|
| Additional Information | Have you got any qualifications? [url=https://www.valeriecolasdesfrancs.com/rogaine-heart-tezr]rogaine funciona mesmo[/url] Hanmi's potential encroachment poses a threat to AstraZeneca, which is facing the near-term expiration of U.S. patents covering its two top-selling drugs - Nexium, which loses U.S. protection in 2014, and the cholesterol pill Crestor, which will go off-patent in 2016. As a result, sales at the company are set to fall by several billion dollars.
|
|---|
| Tags | EZXWxWDLzUQROkaj |
|---|
| Attach Tags | |
|---|